Analysts' Actions: ANR, BTU, GIS, GME

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Alpha Natural ( ANR) was downgraded at Dahlman Rose from Buy to Hold. Company is leveraged to lower met coal pricing, Dahlman Rose said.

Peabody Energy ( BTU) was downgraded at Dahlman Rose from Buy to Hold. It will take time for coal demand to catch up with supply, Dahlman Rose said.

Conagra ( CAG) was upgraded at JP Morgan from Neutral to Overweight. Valuation call, based on a $29 price target, JP Morgan said.

CSX ( CSX) was downgraded at Dahlman Rose from Buy to Hold, Dahlman Rose said. Company is leveraged to lower coal volume and pricing, Dahlman Rose said.

General Mills ( GIS) was downgraded at JP Morgan from Overweight to Neutral. $40 price target. Company will likely take longer to fix its yogurt problems, JP Morgan said.

Gamestop ( GME) was upgraded at Goldman Sachs to Buy. $25 price target. Estimates were also boosted, as the company will likely buy back more stock, Goldman said.

Humana ( HUM) was upgraded at Leerink Swann from Market Perform to Outperform. Company can address margin issues in the coming quarters, Leerink Swann said.

Informatica ( INFA) was upgraded at Baird from Neutral to Outperform. $40 price target. Majority of the company's challenges are fixable, Baird said.

Ingersoll-Rand ( IR) was downgraded at Bank of America/Merrill Lynch to Neutral. Valuation call, based on a $48 price target, BofA/Merrill said.

Manchester United ( MANU) was initiated with a Neutral rating at Nomura. $13 price target. Expect player costs to keep rising, Nomura said.

Manchester United was started with a Buy rating at Deutsche Bank. $17 price target. Expect solid revenue grew, driven by better team performance, Deutsche said.

Norfolk Southern ( NSC) was downgraded at Dahlman Rose from Buy to Hold. Met coal export prices are declining, Dahlman Rose said.

Northwestern ( NEW) was downgraded from Outperform to Neutral at Robert Baird said. Valuation call, based on a $38 price target, Baird said.

NYSE Euronext ( NYX) was upgraded at Keefe, Bruyette & Woods from Market Perform to Outperform. Valuation call, based on a $29 price target, KBW said.

Tivo ( TIVO) was upgraded at JP Morgan from Neutral to Overweight. $13 price target. Company is at an inflection point, with potential catalysts ahead, JP Morgan said.

Walter Energy ( WLT) was downgraded at Dahlman Rose from Buy to Hold. Estimates also cut, given lower expected met coal prices, Dahlman Rose said.

STOCK COMMENTS / EPS CHANGES

Apple ( AAPL) estimates, target were increased at Wedbush. Estimates were raised through 2013. Expect an earlier iPhone 5 launch and mini iPad introduction in 2013, Wedbush said. Outperform rating and new $885 price target.

Autozone ( AZO) was cut from the Conviction Buy List at Goldman Sachs. $415 price target. Sector growth has been slowing, Goldman said. Buy rating.

Celgene ( CELG) price target was boosted at BMO Capital to $90. Revlimid patents should hold up well against generic challenges, BMO said. Outperform rating.

Greenhill ( GHL) estimates, target boosted at Credit Suisse. Shares are now seen reaching $48. Estimates were also increased, as the company is carrying a lot of momentum into the second half of the year, Credit Suisse said. Neutral rating.

Intel ( INTC) estimates, price target were cut at Credit Suisse. Shares are now seen reaching $32. Estimates were also reduced, given lower PC demand. Outperform rating.

Intuitive Surgical ( ISRG) numbers were cut at JMP Securities. Shares are now seen reaching $625. Estimates were also reduced, given weaker pricing, JMP said. Outperform rating.

Labcorp ( LH) estimates were raised at Piper Jaffray through 2013. Medtox acquisition should add to earnings, Piper said. Neutral rating and $91 price target.

Medivation ( MDVN) numbers were raised at Jefferies. Shares are now seen reaching $122. Estimates were also raised on Xtandi approval, Jefferies said. Buy rating.

Medivation estimates, target raised at Credit Suisse. Shares are now seen reaching $149. Estimates were also increased, given the earlier-than-expected approval of Xtandi, Credit Suisse said. Outperform rating.

Ixia ( XXIA) estimates, price target were raised at Lazard. Shares are now seen reaching $17. Estimates were also increased, following upbeat meetings with management, Lazard said. Buy rating.

Zimmer ( ZMH) price target was boosted at Bank of America/Merrill Lynch. Shares are now seen reaching $72. Growth should accelerate in 2013, BofA/Merrill said. Buy rating.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.